Boston Scientific announces favorable study data for its FARAPULSE PFA system and WATCHMAN FLX device at the AF Symposium 2025.

Boston Scientific (NYSE: BSX) today reported data from separate studies backing its Farapulse and Watchman FLX systems.

US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients ...

With Watchman, Boston Scientific estimates a 20% compound annual growth rate (CAGR) in 2025 with a high market share. Mahoney ...

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSETM Pulsed ...

NYSE:BSX) Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation ...

also known as non-valvular AFib or NVAF. Washington Regional’s Walker Heart Institute now offers the Watchman FLX Pro Left ...